Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
CRP (mg/dL) at end of study · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Patients with active Crohn's disease
It is very uncertain whether cannabis oil (5% cannabidiol sublingual oil) changes serious adverse events compared with placebo oil (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical remission · Patients with active Crohn's disease
It is very uncertain whether cannabis oil (5% cannabidiol sublingual oil) changes proportion of patients achieving clinical remission compared with placebo oil (very low certainty).
1 finding from 1 review
Proportion of patients achieving clinical response · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Seizure freedom · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with ≥ 75% reduction in all seizures · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
50% or greater reduction in seizure frequency · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Cannabidiol (10 mg/kg and 20 mg/kg) plus ASMs leads to higher number of participants with adverse events leading to study… compared with placebo plus ASMs (high certainty).
1 finding from 1 review